<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2023.1357286</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Photobiomodulation and phototherapy in skin diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hamblin</surname> <given-names>Michael R.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/48069/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wen</surname> <given-names>Xiang</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/2076533/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname> <given-names>Bingrong</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1806099/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laser Research Centre, Faculty of Health Sciences, University of Johannesburg</institution>, <addr-line>Doornfontein</addr-line>, <country>South Africa</country></aff>
<aff id="aff2"><sup>2</sup><institution>West China Hospital, Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Dermatology, Nanjing Medical University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Robert Gniadecki, University of Alberta, Canada</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Michael R. Hamblin <email>hamblin.lab&#x00040;gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>01</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>10</volume>
<elocation-id>1357286</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>12</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>12</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2024 Hamblin, Wen and Zhou.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Hamblin, Wen and Zhou</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/52237/photobiomodulation-and-phototherapy-in-skin-diseases" ext-link-type="uri">Editorial on the Research Topic <article-title>Photobiomodulation and phototherapy in skin diseases</article-title></related-article>
<kwd-group>
<kwd>dermatology</kwd>
<kwd>lasers - therapeutic use</kwd>
<kwd>acne (acne vulgaris)</kwd>
<kwd>cosmetic</kwd>
<kwd>phototherapy</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="10"/>
<page-count count="3"/>
<word-count count="1789"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Dermatology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Skin is the organ which is most extensively exposed to a broad range of wavelengths of light. Photobiomodulation and phototherapy are becoming promising therapeutic approaches for treating a wide range of cutaneous diseases and disorders, including psoriasis, acne, atopic dermatitis, hair regrowth, wound healing, skin rejuvenation, and pigmentation disorders. Light-based approaches have the advantages of being non-pharmaceutical, easily applied, cost-effective and non-invasive. Various light sources have been investigated, including lasers, intense pulsed light, light-emitting diode arrays, and UV sources. The wavelengths employed range from UV, blue, green, yellow, red to near-infrared. Although some of the light sources are pulsed, others are continuous wave mode. Power levels can vary from highly focused lasers that cause microscopic thermal damage to low-level light that triggers cellular signaling pathways. Some light sources are designed to target specific biological chromophores in the tissue, including blood vessels, melanin, cellular mitochondria, and light-activated ion channels. Different biological structures, including stem cells, immune cells, hair follicles, collagen, and bacteria colonizing the skin can be affected. The strong growth in the practice of Cosmetic Dermatology as world populations have grown in affluence and the usage of social media, has encouraged the use of phototherapy approaches, because there is an understandable reluctance of many patients to take drugs to improve their cosmetic appearance.</p>
<p>This Research Topic was designed to foster insights into advances in the mechanisms and application of photobiomodulation and phototherapy for skin diseases in order to provoke further translational research in this area. We eventually ended up with two original research papers, two brief research reports, one clinical trial and one case report.</p>
<p>The first research report was by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fvets.2023.1155105">Marchegiani et al.</ext-link> who investigated the use of fluorescent light energy (FLE) to treat canine superficial bacterial folliculitis. Superficial bacterial folliculitis (SBF) is a bacterial infection that is confined within the hair follicles, without invasion of the dermis (<xref ref-type="bibr" rid="B1">1</xref>). <italic>Staphylococcus pseudintermedius</italic> is a normal commensal species in canine skin and is the main cause of SBF (<xref ref-type="bibr" rid="B2">2</xref>). Topical and systemic antibiotics are the most often employed treatments for canine SBF, but antibiotic resistance is a growing problem. FLE consisted of applying a layer of yellow gel containing fluorescent dyes to the affected skin and then irradiating with blue light (440 nm&#x02212;460 nm, 55&#x02013;129 mW/cm<sup>2</sup>) for 2 min. Six dogs received FLE once, six dogs twice, while eight dogs received oral antibiotics until complete healing was observed. FLE was able to significantly reduce the time needed for clinical resolution compared to antibiotics alone, improving the owners&#x00027; compliance and welfare of the dogs.</p>
<p>The second research report was by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1170520">Hu et al.</ext-link> who carried out a retrospective evaluation of hemoporfin-mediated photodynamic therapy (HM-PDT) for port-wine stains. Hemoporfin is hematoporphyrin monomethyl ether and has been shown to be effective in destroying the abnormal vasculature after IV administration and activation by green light (<xref ref-type="bibr" rid="B3">3</xref>). Because PDT can be very painful, general anesthesia is sometimes employed in patients who would otherwise be unable to tolerate the procedure. This paper asked the question whether the use of general anesthesia affected the outcome of the PDT on the port wine stain. They looked at 207 patients treated with HM-PDT of whom 137 received a general anesthetic, while 69 did not. The treatment efficacy was significantly higher in the general anesthetic group than in the non-anesthetic group (76.81% vs. 56.52%, <italic>p</italic> &#x0003C; 0.05). Purpura lasted longer in the anesthetic group, but the other side effects were similar between the two groups.</p>
<p>Solar lentigenes are disfiguring brown spots on the face, which are often treated with a picosecond pulsed 755-nm alexandrite laser especially in Asian skin types (<xref ref-type="bibr" rid="B4">4</xref>). In a brief research report, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1158842">Liu et al.</ext-link> asked whether video education could improve the process of obtaining informed consent for this procedure. In a retrospective study they compared 56 patients who received additional video education, while 50 patients underwent traditional informed consent. More correct answers were given by older and less educated patients who received video education, while the video group also reported improved patient satisfaction compared to the traditional group.</p>
<p>The second brief research report by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1275912">Yu et al.</ext-link> described a prospective randomized half-body study comparing 308 nm LED light vs. 308 nm excimer laser for treating localized psoriasis. The 308 nm excimer laser has been used to treat psoriasis since 2000 (<xref ref-type="bibr" rid="B5">5</xref>), but the device is expensive and bulky. Ten patients with symmetrical skin lesions of mild-to-moderate psoriasis completed a prospective, randomized, split sided clinical trial. The target lesions were randomly treated with either LED light or excimer laser twice a week for 12 weeks. The responses as evaluated by the local psoriasis severity index scores and dermoscopic features were similar on both sides of the body. Because 308 nm LEDS are more portable and cost-effective compared to the excimer laser, they should be considered in the future for psoriasis treatment.</p>
<p>The clinical trial was conducted by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1248831">Dai et al.</ext-link> who investigated the laser treatment of atrophic acne scars in Asian patients. Atrophic acne scars are a disfiguring and distressing complication of acne which may affect up to 95% of patients (<xref ref-type="bibr" rid="B6">6</xref>). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1248831">Dai et al.</ext-link> carried out a 20-week prospective, randomized, split-face, controlled pilot study comparing 1064-nm Nd:YAG picosecond laser using a fractional micro-lens array (P-MLA) vs. an ablative fractional 2940-nm Er:YAG laser (AF-Er) in 31 patients. The Echelle d&#x00027;Evaluation Clinique des Cicatrices d&#x00027;acne (ECCA) grading scale, Investigator Global Assessment (IGA) scores, patient satisfaction, and VISIA analysis were employed to evaluate the improvement in the scars. Both lasers produced equivalent improvements in ECCA and IGA scores, but patient satisfaction was higher for the AF-Er-treated side. VISIA analysis revealed the pore and skin texture was similar for both devices. No serious side effects were reported, but the P-MLA side had less pain and shorter duration of crust shedding and edema.</p>
<p>The final case report by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1187186">Ping et al.</ext-link> described the treatment of a patient with acne vulgaris using a combination of 5-aminolaevulinic acid mediated photodynamic therapy and the monoclonal antibody adalimumab. Adalimumab (also known as Humira) binds to and inactivates the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-a) (<xref ref-type="bibr" rid="B7">7</xref>). It has used to treat many chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn&#x00027;s disease, and ulcerative colitis (<xref ref-type="bibr" rid="B8">8</xref>), but has not often been used as a monotherapy for acne (<xref ref-type="bibr" rid="B9">9</xref>). ALA-PDT is often used for treating recalcitrant acne due to its ability to reduce sebum secretion while at the same time killing the <italic>Cutibacterium acnes</italic> bacteria, which colonize the sebaceous glands (<xref ref-type="bibr" rid="B10">10</xref>). The patient who suffered from severe acne and had previously failed other therapies, was treated with ALA PDT once a week for 3 weeks and three injection of Humira once every 2 weeks. The active acne lesions then resolved leaving some residual scars.</p>
<p>We hope that these papers in the present Research Topic will encourage other clinicians to further explore the wide range of phototherapy options for skin diseases, including sophisticated lasers and more economical LEDs, as well as simple lamps.</p>
<sec sec-type="author-contributions" id="s1">
<title>Author contributions</title>
<p>MH: Writing&#x02014;original draft, Writing&#x02014;review &#x00026; editing. XW: Writing&#x02014;original draft, Writing&#x02014;review &#x00026; editing. BZ: Writing&#x02014;original draft, Writing&#x02014;review &#x00026; editing.</p></sec>
</body>
<back>
<sec sec-type="funding-information" id="s2">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname> <given-names>P</given-names></name></person-group>. <article-title>Canine superficial bacterial folliculitis: current understanding of its etiology, diagnosis and treatment</article-title>. <source>The Vet J.</source> (<year>2014</year>) <volume>199</volume>:<fpage>217</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.tvjl.2013.11.014</pub-id><pub-id pub-id-type="pmid">24345778</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname> <given-names>RF</given-names></name> <name><surname>Boysen</surname> <given-names>L</given-names></name> <name><surname>Jessen</surname> <given-names>LR</given-names></name> <name><surname>Guardabassi</surname> <given-names>L</given-names></name> <name><surname>Damborg</surname> <given-names>P</given-names></name></person-group>. <article-title>Diversity of Staphylococcus pseudintermedius in carriage sites and skin lesions of dogs with superficial bacterial folliculitis: potential implications for diagnostic testing and therapy</article-title>. <source>Vet Dermatol.</source> (<year>2018</year>) <volume>29</volume>:<fpage>291</fpage>&#x02013;<lpage>e100</lpage>. <pub-id pub-id-type="doi">10.1111/vde.12549</pub-id><pub-id pub-id-type="pmid">29781542</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Y</given-names></name> <name><surname>Gong</surname> <given-names>W</given-names></name> <name><surname>Kang</surname> <given-names>J</given-names></name> <name><surname>Fang</surname> <given-names>Y</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name> <name><surname>Lin</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Hemoporfin-mediated photodynamic therapy for port-wine stains: multivariate analysis of clinical efficacy and optical coherence tomography appearance</article-title>. <source>Front Med.</source> (<year>2022</year>) <volume>9</volume>:<fpage>800836</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2022.800836</pub-id><pub-id pub-id-type="pmid">35280862</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>JCY</given-names></name> <name><surname>Shek</surname> <given-names>SYN</given-names></name> <name><surname>Kono</surname> <given-names>T</given-names></name> <name><surname>Yeung</surname> <given-names>CK</given-names></name> <name><surname>Chan</surname> <given-names>HHL</given-names></name></person-group>. <article-title>A retrospective analysis on the management of pigmented lesions using a picosecond 755-nm alexandrite laser in Asians</article-title>. <source>Lasers Surg Med.</source> (<year>2016</year>) <volume>48</volume>:<fpage>23</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/lsm.22443</pub-id><pub-id pub-id-type="pmid">26696500</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asawanonda</surname> <given-names>P</given-names></name> <name><surname>Anderson</surname> <given-names>RR</given-names></name> <name><surname>Chang</surname> <given-names>Y</given-names></name> <name><surname>Taylor</surname> <given-names>CR</given-names></name></person-group>. <article-title>308-nm excimer laser for the treatment of psoriasis: a dose-response study</article-title>. <source>Arch Dermatol.</source> (<year>2000</year>) <volume>136</volume>:<fpage>619</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1001/archderm.136.5.619</pub-id><pub-id pub-id-type="pmid">10815855</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hession</surname> <given-names>MT</given-names></name> <name><surname>Graber</surname> <given-names>EM</given-names></name></person-group>. <article-title>Atrophic acne scarring: a review of treatment options</article-title>. <source>J Clin Aesthet Dermatol.</source> (<year>2015</year>) <volume>8</volume>:<fpage>50</fpage>.<pub-id pub-id-type="pmid">25610524</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kupper</surname> <given-names>H</given-names></name> <name><surname>Salfeld</surname> <given-names>J</given-names></name> <name><surname>Tracey</surname> <given-names>D</given-names></name> <name><surname>Kalden</surname> <given-names>JR</given-names></name></person-group>. <article-title>Adalimumab (Humira)</article-title>. <source>Handb Ther Antibodies.</source> (<year>2007</year>) <volume>21</volume>:<fpage>696</fpage>&#x02013;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1002/9783527619740.ch27</pub-id></citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brankov</surname> <given-names>N</given-names></name> <name><surname>Jacob</surname> <given-names>SE</given-names></name></person-group>. <article-title>Adalimumab</article-title>. <source>J Dermatol Nurses&#x00027; Assoc.</source> (<year>2016</year>) <volume>8</volume>:<fpage>216</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1097/JDN.0000000000000229</pub-id></citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miguel</surname> <given-names>D</given-names></name> <name><surname>Tittelbach</surname> <given-names>J</given-names></name> <name><surname>Elsner</surname> <given-names>P</given-names></name></person-group>. <article-title>A dramatic case of acne fulminans responding to adalimumab</article-title>. <source>JDDG.</source> (<year>2019</year>) <volume>17</volume>:<fpage>837</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/ddg.13842</pub-id><pub-id pub-id-type="pmid">31056852</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>P</given-names></name> <name><surname>Wang</surname> <given-names>B</given-names></name> <name><surname>Zhang</surname> <given-names>L</given-names></name> <name><surname>Liu</surname> <given-names>X</given-names></name> <name><surname>Shi</surname> <given-names>L</given-names></name> <name><surname>Kang</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Clinical practice guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China</article-title>. <source>Photodiagnosis Photodyn Ther.</source> (<year>2022</year>) <volume>10</volume>:<fpage>103261</fpage>. <pub-id pub-id-type="doi">10.1016/j.pdpdt.2022.103261</pub-id><pub-id pub-id-type="pmid">36587863</pub-id></citation></ref>
</ref-list>
</back>
</article>